Barriers to satisfactory migraine outcomes. what have we learned, where do we stand?: Views and perspectives

Headache

Volumn 49, Issue 7, 2009, Pages 1028-1041

  Bigal, Marcelo ^a,c   Krymchantowski, Abouch Valenty ^b   Lipton, Richard B ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Barriers to care; Migraine outcomes; Satisfaction

Indexed keywords

ANTIMIGRAINE AGENT; BUTALBITAL; OPIATE; PARACETAMOL; TRIPTAN DERIVATIVE;

ADULT; AGED; AWARENESS; COST EFFECTIVENESS ANALYSIS; DENMARK; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; FUNDING; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; OUTCOMES RESEARCH; PAIN ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVIEW; SINUS HEADACHE; TENSION HEADACHE; THERAPY DELAY; UNITED STATES;

COMMUNICATION BARRIERS; HUMANS; MIGRAINE DISORDERS; PHYSICIAN-PATIENT RELATIONS; QUESTIONNAIRES; REFERRAL AND CONSULTATION; TREATMENT OUTCOME;

EID: 67651184037     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2009.01410.x     Document Type: Review

References (97)

1. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 68 : 343 349.
2. Stovner L, Hagen K, Jensen R, et al. The global burden of headache: A documentation of headache prevalence and disability worldwide. Cephalalgia. 2007 27 : 193 210.
3. Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics. 1998 13 : 667 676.
4. Solomon GD, Price KL. Burden of migraine. A review of its socioeconomic impact. Pharmacoeconomics. 1997 11 (Suppl. 1 1 10.
5. Steiner TJ. Lifting the burden: The global campaign against headache. Lancet Neurol. 2004 3 : 204 205.
6. Lipton RB, Amatniek JC, Ferrari MD, Gross M. Migraine. Identifying and removing barriers to care. Neurology. 1994 44 : S63 68.
7. Wenzel R, Dortch M, Cady R, et al. Migraine headache misconceptions: Barriers to effective care. Pharmacotherapy. 2004 24 : 638 648.
8. Campinha-Bacote DL, Kendle JB, Jones C, et al. Impact of a migraine management program on improving health outcomes. Dis Manag. 2005 8 : 382 391.
9. Silberstein SD, Dodick D, Kesslick J. Removing barriers to appropriate migraine treatment: Formulary limitations and triptan package size. Headache. 2005 45 : 1250 1254.
10. Lipton RB, Bigal ME. Headache as a real disease. Headache. 2008 48 : 707 710.
11. Steiner TJ. Lifting the burden: The global campaign to reduce the burden of headache worldwide. J Headache Pain. 2005 6 : 373 377.
12. Martelletti P, Haimanot RT, Lainez MJ, et al. The Global Campaign (GC) to Reduce the Burden of Headache Worldwide. The International Team for Specialist Education (ITSE). J Headache Pain. 2005 6 : 261 263.
13. Linde M, Jonsson P, Hedenrud T. Influence of disease features on adherence to prophylactic migraine medication. Acta Neurol Scand. 2008.
14. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: Results from the American Migraine Study. Headache. 1998 38 : 87 96.
15. Lipton RB, Diamond S, Reed M, et al. Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache. 2001 41 : 638 645. (Pubitemid 32777746)
16. Becker WJ, Giammarco R, Wiebe V. Moving forward to improve migraine management in Canada. Can J Neurol Sci. 2007 34 : S20 26.
17. Badia X, Magaz S, Gutierrez L, Galvan J. The burden of migraine in Spain: Beyond direct costs. Pharmacoeconomics. 2004 22 : 591 603.
18. Scary E. The Body in Pain: The Making and Unmaking of the World, 1st edn. New York : Oxford University Press 2001 : 400.
19. Goubert L, Craig KD, Vervoort T, et al. Facing others in pain: The effects of empathy. Pain. 2005 118 : 285 288.
20. Passik SD, Byers K, Kirsh KL. Empathy and the failure to treat pain. Palliat Support Care. 2007 5 : 167 172.
21. Jackson PL, Rainville P, Decety J. To what extent do we share the pain of others? Insight from the neural bases of pain empathy. Pain. 2006 125 : 5 9.
22. Gallagher RM. Empathy: A timeless skill for the pain medicine toolbox. Pain Med. 2006 7 : 213 214.
23. Jackson PL, Decety J. Motor cognition: A new paradigm to study self-other interactions. Curr Opin Neurobiol. 2004 14 : 259 263.
24. Ruby P, Decety J. How would you feel versus how do you think she would feel? A neuroimaging study of perspective-taking with social emotions. J Cogn Neurosci. 2004 16 : 988 999.
25. Preston SD, de Waal FB. Empathy: Its ultimate and proximate bases. Behav Brain Sci. 2002 25 : 1 20 discussion 20-71.
26. Botvinick M, Jha AP, Bylsma LM, et al. Viewing facial expressions of pain engages cortical areas involved in the direct experience of pain. Neuroimage. 2005 25 : 312 319.
27. Evans RW, Lipton RB, Ritz KA. A survey of neurologists on self-treatment and treatment of their families. Headache. 2007 47 : 58 64.
28. Evans RW, Lipton RB, Silberstein SD. The prevalence of migraine in neurologists. Neurology. 2003 61 : 1271 1272.
29. Halamek LP. Teaching versus learning and the role of simulation-based training in pediatrics. J Pediatr. 2007 151 : 329 330.
30. Hirschhorn NH, Lamstein J, Klein SF, et al. Quality by objectives: A model of quality of care assessment and assurance for ambulatory health centers. J Ambul Care Manage. 1978 1 : 55 73.
31. Bergen DC, Good D. Neurology training programs worldwide: A world federation of neurology survey. J Neurol Sci. 2006 246 : 59 64.
32. Jozefowicz RF. Neurology residency training in the US and Poland. Nat Clin Pract Neurol. 2007 3 : 586 587.
33. Bergen DC, Silberberg D. Nervous system disorders: A global epidemic. Arch Neurol. 2002 59 : 1194 1196.
34. Menken M, Munsat TL, Toole JF. The global burden of disease study: Implications for neurology. Arch Neurol. 2000 57 : 418 420.
35. Murray CJ, Lopez AD, Black R, et al. Global burden of disease 2005: Call for collaborators. Lancet. 2007 370 : 109 110.
36. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet. 2006 367 : 1747 1757.
37. Rodgers A, Ezzati M, Vander Hoorn S, et al. Distribution of major health risks: Findings from the Global Burden of Disease study. PLoS Med. 2004 1. e27
38. Silberstein SD. Clinical practice guidelines. Cephalalgia. 2005 25 : 765 766.
39. Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000 55 : 754 762.
40. Pryse-Phillips WE, Dodick DW, Edmeads JG, et al. Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. CMAJ. 1997 156 : 1273 1287.
41. Lipton RB, Bigal ME. Ten lessons on the epidemiology of migraine. Headache. 2007 47 (Suppl. 1 S2 9.
42. Olesen J, Lekander I, Andlin-Sobocki P, Jonsson B. Funding of headache research in Europe. Cephalalgia. 2007 27 : 995 999.
43. Shapiro RE, Goadsby PJ. The long drought: The dearth of public funding for headache research. Cephalalgia. 2007 27 : 991 994.
44. Shapiro RE. NIH funding for research on headache disorders: Does it matter? Headache. 2007 47 : 993 995.
45. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001 41 : 646 657.
46. Lipton RB, Scher AI, Kolodner K, et al. Migraine in the United States: Epidemiology and patterns of health care use. Neurology. 2002 58 : 885 894.
47. Lucas C, Geraud G, Valade D, et al. Recognition and therapeutic management of migraine in 2004, in France: Results of FRAMIG 3, a French nationwide population-based survey. Headache. 2006 46 : 715 725.
48. Medrano Martinez V, Esquembre R, Genoves A. Headache, does it cause a health care overload in primary health care? Urban area vs rural area medical visit. Neurologia. 2008 23 : 269 274.
49. Lanteri-Minet M, Valade D, Geraud G, et al. Migraine and probable migraine - Results of FRAMIG 3, a French nationwide survey carried out according to the 2004 IHS classification. Cephalalgia. 2005 25 : 1146 1158.
50. Lucas C, Chaffaut C, Artaz MA, Lanteri-Minet M. FRAMIG 2000: Medical and therapeutic management of migraine in France. Cephalalgia. 2005 25 : 267 279.
51. Latinovic R, Gulliford M, Ridsdale L. Headache and migraine in primary care: Consultation, prescription, and referral rates in a large population. J Neurol Neurosurg Psychiatry. 2006 77 : 385 387.
52. Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from the American Migraine Prevalence and Prevention study. Headache. 2007 47 : 355 363.
53. Solomon GD, Santanello N. Impact of migraine and migraine therapy on productivity and quality of life. Neurology. 2000 55 : S29 35.
54. Dowson A, Jagger S The UK migraine patient survey: Quality of life and treatment. Curr Med Res Opin. 1999 15 : 241 253.
55. Garcia ML, Baos V, Lainez M, et al. Responsiveness of migraine-ACT and MIDAS questionnaires for assessing migraine therapy. Headache. 2008 48 : 1349 1355.
56. Pascual J, Lainez MJ, Baos V, et al. Predictive model for the Migraine-ACT questionnaire in primary care. Curr Med Res Opin. 2007 23 : 3033 3039.
57. Schiller F. The migraine tradition. Bull Hist Med. 1975 49 : 1 19.
58. Edmeads J. History of migraine treatment. Can J Clin Pharmacol. 1999 6 (Suppl. A 5A 8A.
59. Morillo LE, Alarcon F, Aranaga N, et al. Clinical characteristics and patterns of medication use of migraneurs in Latin America from 12 cities in 6 countries. Headache. 2005 45 : 118 126.
60. Diener HC, Agosti R, Allais G, et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2007 6 : 1054 1062.
61. Bordini CA, Mariano da Silva H, Garbelini RP, et al. Effect of preventive treatment on health-related quality of life in episodic migraine. J Headache Pain. 2005 6 : 387 391.
62. Cady R, Martin V, Mauskop A, et al. Efficacy of rizatriptan 10 mg administered early in a migraine attack. Headache. 2006 46 : 914 924.
63. Mathew NT, Finlayson G, Smith TR, et al. Early intervention with almotriptan: Results of the AEGIS trial (AXERT Early Migraine Intervention Study). Headache. 2007 47 : 189 198.
64. Brandes JL, Kudrow D, Cady R, et al. Eletriptan in the early treatment of acute migraine: Influence of pain intensity and time of dosing. Cephalalgia. 2005 25 : 735 742.
65. Ferrari MD. Should we advise patients to treat migraine attacks early: Methodologic issues. Eur Neurol. 2005 53 (Suppl. 1 17 21.
66. Ivers H, McGrath PJ, Purdy RA, et al. Decision making in migraine patients taking sumatriptan: An exploratory study. Headache. 2000 40 : 129 136.
67. Foley KA, Cady R, Martin V, et al. Treating early versus treating mild: Timing of migraine prescription medications among patients with diagnosed migraine. Headache. 2005 45 : 538 545.
68. Ifergane G, Wirguin I, Shvartzman P. Triptans - Why once? Headache. 2006 46 : 1261 1263.
69. Sheftell FD, Feleppa M, Tepper SJ, et al. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache. 2004 44 : 661 668.
70. Feleppa M, Apice G, D'Alessio A, et al. Tolerability of acute migraine medications: Influence of methods of assessment and relationship with headache attributes. Cephalalgia. 2008.
71. Sheftell FD, Tepper SJ, Bigal ME. Migraine: Barriers for care. Neurol Sci. 2005 26 (Suppl. 2 s140 142.
72. Edvinsson L, Uddman E, Wackenfors A, et al. Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: Relationship to clinical effect. Clin Sci (Lond). 2005 109 : 335 342.
73. Nilsson T, Longmore J, Shaw D, et al. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol. 1999 372 : 49 56.
74. Evers S, Husstedt IW, Enbergs A. Coronary angiography in migraine patient after subcutaneous sumatriptan. Lancet. 1995 345 : 198.
75. Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study. Headache. 2008 48 : 1157 1168.
76. Shimony A, Romem A, Horowitz S, et al. Acute coronary syndrome associated with myocardial bridging due to ergotamine treatment for migraine. Int J Cardiol. 2006 113 : E7 8.
77. Vega D, Maalouf NM, Sakhaee K. Increased propensity for calcium phosphate kidney stones with topiramate use. Expert Opin Drug Saf. 2007 6 : 547 557.
78. Russell MB, Olesen J. Migrainous disorder and its relation to migraine without aura and migraine with aura. A genetic epidemiological study. Cephalalgia. 1996 16 : 431 435.
79. Patel NV, Bigal ME, Kolodner KB, et al. Prevalence and impact of migraine and probable migraine in a health plan. Neurology. 2004 63 : 1432 1438.
80. Silberstein S, Loder E, Diamond S, et al. Probable migraine in the United States: Results of the American Migraine Prevalence and Prevention (AMPP) study. Cephalalgia. 2007 27 : 220 234.
81. Bigal ME, Kolodner KB, Lafata JE, et al. Patterns of medical diagnosis and treatment of migraine and probable migraine in a health plan. Cephalalgia. 2006 26 : 43 49.
82. Castillo J, Munoz P, Guitera V, Pascual J. Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache. 1999 39 : 190 196.
83. Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache. 1998 38 : 497 506.
84. Lipton RB, Bigal ME, Ashina S, et al. Cutaneous allodynia in the migraine population. Ann Neurol. 2008 63 : 148 158.
85. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment. Neurology. 2008 71 : 559 566.
86. Schulman EA, Lake AE 3rd., Goadsby PJ, et al. Defining refractory migraine and refractory chronic migraine: Proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache. 2008 48 : 778 782.
87. Eadie MJ. The pathogenesis of migraine - 17th to early 20th century understandings. J Clin Neurosci. 2005 12 : 383 388.
88. Haut SR, Bigal ME, Lipton RB. Chronic disorders with episodic manifestations: Focus on epilepsy and migraine. Lancet Neurol. 2006 5 : 148 157.
89. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache. 2006 46 : 1334 1343.
90. Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003 106 : 81 89.
91. Silberstein S, Diener HC, Lipton R, et al. Epidemiology, risk factors, and treatment of chronic migraine: A focus on topiramate. Headache. 2008 48 : 1087 1095.
92. Lanteri-Minet M. Identification of chronic daily headache risk factors to prevent migraine progression. Rev Prat. 2008 58 : 639 642.
93. Hung CI, Wang SJ, Hsu KH, et al. Risk factors associated with migraine or chronic daily headache in out-patients with major depressive disorder. Acta Psychiatr Scand. 2005 111 : 310 315.
94. Karakurum B, Soylu O, Karatas M, et al. Personality, depression, and anxiety as risk factors for chronic migraine. Int J Neurosci. 2004 114 : 1391 1399.
95. Dodick D, Freitag F. Evidence-based understanding of medication-overuse headache: Clinical implications. Headache. 2006 46 (Suppl. 4 S202 211.
96. Wilkinson SM, Becker WJ, Heine JA. Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache. 2001 41 : 303 309.
97. Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache. 2003 43 : 179 190.